Stock A016450 HANSAE YES24 HOLDINGS CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Hansae Yes24 Holdings Co., Ltd

Equities

A016450

KR7016450009

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 27/06/2024 BST 		5-day change 1st Jan Change
4,700 KRW +1.08% Intraday chart for Hansae Yes24 Holdings Co., Ltd -1.16% -4.08%
05-16 Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-20 Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Hansa Biopharma: increase in number of shares and votes
AQ
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
AQ
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
AQ
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
AQ
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
AQ
Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Correction, Hansa Biopharma, increase in number of shares and votes
AQ
Hansa Biopharma: increase in number of shares and votes
AQ
Hansa Biopharma interim report January-March 2024
AQ
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)
AQ
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports
AQ
Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
AQ
Hansa Biopharma Year-end report January-December 2023
AQ
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
AQ
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
AQ
Hansa Biopharma Nomination Committee formed
AQ
Hansa Biopharma - Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 Trial in Guillain-Barre Syndrome
AQ
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A016450 Stock
  4. News Hansae Yes24 Holdings Co., Ltd